Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

IDE892

Small molecule · Inhibitor of PRMT5 · developed by IDEAYA Biosciences

Phase 1 Most advanced trial
IDYA Developer
1 Registered trials

What is IDE892?

IDE892 is an orally bioavailable, methylthioadenosine (MTA)-selective inhibitor of protein arginine methyltransferase 5 (PRMT5). It binds PRMT5 when it is complexed with MTA, a complex elevated in MTAP-deleted cancer cells, reducing histone arginine methylation and proliferation in those cells. It is being studied in advanced or metastatic cancers harboring MTAP deletions.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
PRMT5
Mechanism
Inhibitor of PRMT5
Pathways
histone arginine methylation, gene expression regulation, cellular proliferation, apoptosis
Therapy area
Oncology
Developer
IDEAYA Biosciences (IDYA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07277413 Phase 1 NSCLC Adenocarcinoma Recruiting IDYA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Adenocarcinoma of EsophagusBiliary Tract CarcinomaBladder CancerGastric AdenocarcinomaGastroesophageal Cancer (GC)MesotheliomaNon-Small Cell Lung Cancer NSCLCNSCLC AdenocarcinomaPancreatic CancerPeritoneal MesotheliomaPleural MesotheliomaSquamous Cell Car. - EsophagusUrothelial Carcinoma (UC)

Other drugs acting on PRMT5

More from IDEAYA Biosciences

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the IDYA page.

Follow IDYA, the company behind IDE892

See IDYA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IDYA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.